Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.39 |
| ▸ | METAP2 | P50579 | 2/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.37 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.37 |
| ▸ | AXL | P30530 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11577531 | 0.79 | NOS1 (0.53) | NOS1MAPTKDM4EMEN1KMT2A | |
| SCHEMBL2425031 | 0.78 | NOS1 (0.52) | NOS1MAPTCHEK1METAP2DYRK1A | |
| SCHEMBL1286200 | 0.76 | MAPT (0.52) | NOS1MAPTROCK1KDM4EMEN1 | |
| SCHEMBL759126 | 0.76 | NOS1 (0.50) | NOS1MAPTROCK1KDM4EMEN1 | |
| SCHEMBL3515094 | 0.76 | MAPT (0.46) | NOS1MAPTROCK1KDM4EMEN1 | |
| SCHEMBL30099420 | 0.76 | NOS1 (0.50) | NOS1MAPTCHEK1METAP2DYRK1A | |
| SCHEMBL2430496 | 0.76 | NOS1 (0.50) | NOS1MAPTMEN1KMT2ACHEK1 | |
| SCHEMBL14500106 | 0.76 | NOS1 (0.50) | NOS1MAPTKDM4EALDH1A1HTT | |
| Hydrochloric Acid SCHEMBL15517276 | 0.74 | MAPT (0.50) | MAPTROCK1KDM4EMEN1KMT2A | |
| SCHEMBL25475118 | 0.73 | KDM4E (0.43) | MAPTROCK1KDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250230157-A1 | AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS | RAPPORT THERAPEUTICS, INC. | 2025-07-17 | — | — | US | disclosed |
| WO-2025133191-A1 | NOVEL SULFONAMIDES OR SULFONES AND THEIR USE AS NEUROPROTECTIVE AND/OR NEURORESTORATIVE AGENTS | GENECODE (EE) | 2025-06-26 | — | — | WO | disclosed |
| US-12304908-B2 | Azabenzimidazoles and their use as AMPA receptor modulators | RAPPORT THERAPEUTICS, INC. (US) | 2025-05-20 | — | — | US | disclosed |
| US-12145934-B2 | Azabenzimidazoles and their use as AMPA receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2024-11-19 | — | — | US | disclosed |
| US-12139485-B2 | Azabenzimidazoles and their use as AMPA receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2024-11-12 | — | — | US | disclosed |
| CN-118496159-B | Application of compound in preparation of medicine with liver fibrosis preventing and/or treating effect | 广州医科大学附属市八医院 | 2024-09-24 | — | — | CN | disclosed |
| CN-118496159-A | Application of compound in preparation of medicine with liver fibrosis preventing and/or treating effect | 广州医科大学附属市八医院 | 2024-08-16 | — | — | CN | disclosed |
| US-20230114165-A1 | AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-04-13 | — | — | US | disclosed |
| US-20230110576-A1 | AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-04-13 | — | — | US | disclosed |
| EP-4144736-A1 | AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN Pharmaceutica NV (BE) | 2023-03-08 | — | — | EP | disclosed |
| US-8008481-B2 | Indazole compounds | ABBVIE INC. | 2011-08-30 | — | — | US | disclosed |
| US-8008481-B2 | Indazole compounds | ABBVIE INC. | 2011-08-30 | — | — | US | disclosed |
| US-8008481-B2 | Indazole compounds | ABBVIE INC. | 2011-08-30 | — | — | US | disclosed |
| US-20090069288-A1 | Novel therapeutic compounds | ABBVIE INC. | 2009-03-12 | — | — | US | disclosed |
| EP-2001480-A2 | INDAZOLE COMPOUNDS | Abbott Laboratories (US) | 2008-12-17 | — | — | EP | disclosed |
| US-20070282101-A1 | Indazole compounds | ABBVIE INC. | 2007-12-06 | — | — | US | disclosed |
| US-20070282101-A1 | Indazole compounds | ABBVIE INC. | 2007-12-06 | — | — | US | disclosed |
| US-20070282101-A1 | Indazole compounds | ABBVIE INC. | 2007-12-06 | — | — | US | disclosed |
| WO-2007117465-A2 | INDAZOLE COMPOUNDS | ABBOTT LABORATORIES (US) | 2007-10-18 | — | — | WO | disclosed |
| WO-2007117465-A2 | INDAZOLE COMPOUNDS | ABBOTT LABORATORIES (US) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070282101-A1 | Indazole compounds | CYP3A43, CYP3A7, UGT1A1 | NOS1 849/4885MAPT 2375/4885ROCK1 2438/4885 |
| US-12139485-B2 | Azabenzimidazoles and their use as AMPA receptor modulators | GRIN1, GRIN2B, GRIN3A | NOS1 530/4885MAPT 2655/4885ROCK1 4034/4885 |
| US-12145934-B2 | Azabenzimidazoles and their use as AMPA receptor modulators | GRIN1, GRIN2B, GRIN3A | NOS1 530/4885MAPT 2655/4885ROCK1 4034/4885 |
| US-20230110576-A1 | AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS | GRIN1, GRIN2B, GRIN3A | NOS1 530/4885MAPT 2655/4885ROCK1 4034/4885 |
| US-20090069288-A1 | Novel therapeutic compounds | MAP3K20, RPS6KB1, MAP3K1 | NOS1 900/4885MAPT 3755/4885ROCK1 398/4885 |
| US-12304908-B2 | Azabenzimidazoles and their use as AMPA receptor modulators | GRIN1, GRIN2B, GRIN3A | NOS1 530/4885MAPT 2655/4885ROCK1 4034/4885 |
| US-20230114165-A1 | AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS | GRIN1, GRIN2B, GRIN3A | NOS1 530/4885MAPT 2655/4885ROCK1 4034/4885 |
| US-20250230157-A1 | AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS | GRIN1, GRIN2B, GRIN3A | NOS1 498/4885MAPT 2649/4885ROCK1 3993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.